Clinical Risk Factors and Prognostic Impact of Osteoporosis in Patients With Chronic Heart Failure.


Journal

Circulation journal : official journal of the Japanese Circulation Society
ISSN: 1347-4820
Titre abrégé: Circ J
Pays: Japan
ID NLM: 101137683

Informations de publication

Date de publication:
25 11 2020
Historique:
pubmed: 30 10 2020
medline: 15 12 2021
entrez: 29 10 2020
Statut: ppublish

Résumé

The clinical significance of osteoporosis in chronic heart failure (CHF) remains unclear.Methods and Results:A total of 303 CHF patients (75 years, [interquartile range (IQR) 66-82 years]; 41% female) were retrospectively examined. Bone mineral densities (BMDs) at the lumbar spine, femoral neck, and total femur were measured by using dual-energy X-ray absorptiometry (DEXA), and osteoporosis was diagnosed when the BMD at any of the 3 sites was <70% of the Young Adult Mean percentage (%YAM). The prevalence of osteoporosis in CHF patients was 40%. Patients with osteoporosis were older (79 [IQR, 74-86] vs. 72 [IQR, 62-80] years), included a large percentage of females, had slower gait speed and had a lower body mass index. Multivariate logistic regression analysis indicated that sex, BMI, gait speed, loop diuretics use and no use of direct oral anticoagulants (DOACs) were independently associated with osteoporosis. Kaplan-Meier survival curves showed that the rate of death and heart failure hospitalization was higher in patients with osteoporotic BMD at 2 or 3 sites than in patients without osteoporosis (hazard ratio 3.45, P<0.01). In multivariate Cox regression analyses, osteoporotic BMD at 2 or 3 sites was an independent predictor of adverse events after adjustment for prognostic markers. Loop diuretics use and no DOACs use are independently associated with osteoporosis in CHF patients. Osteoporosis is a novel predictor of worse outcome in patients with CHF.

Sections du résumé

BACKGROUND
The clinical significance of osteoporosis in chronic heart failure (CHF) remains unclear.Methods and Results:A total of 303 CHF patients (75 years, [interquartile range (IQR) 66-82 years]; 41% female) were retrospectively examined. Bone mineral densities (BMDs) at the lumbar spine, femoral neck, and total femur were measured by using dual-energy X-ray absorptiometry (DEXA), and osteoporosis was diagnosed when the BMD at any of the 3 sites was <70% of the Young Adult Mean percentage (%YAM). The prevalence of osteoporosis in CHF patients was 40%. Patients with osteoporosis were older (79 [IQR, 74-86] vs. 72 [IQR, 62-80] years), included a large percentage of females, had slower gait speed and had a lower body mass index. Multivariate logistic regression analysis indicated that sex, BMI, gait speed, loop diuretics use and no use of direct oral anticoagulants (DOACs) were independently associated with osteoporosis. Kaplan-Meier survival curves showed that the rate of death and heart failure hospitalization was higher in patients with osteoporotic BMD at 2 or 3 sites than in patients without osteoporosis (hazard ratio 3.45, P<0.01). In multivariate Cox regression analyses, osteoporotic BMD at 2 or 3 sites was an independent predictor of adverse events after adjustment for prognostic markers.
CONCLUSIONS
Loop diuretics use and no DOACs use are independently associated with osteoporosis in CHF patients. Osteoporosis is a novel predictor of worse outcome in patients with CHF.

Identifiants

pubmed: 33116003
doi: 10.1253/circj.CJ-20-0593
doi:

Substances chimiques

Anticoagulants 0
Sodium Potassium Chloride Symporter Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2224-2234

Auteurs

Satoshi Katano (S)

Division of Rehabilitation, Sapporo Medical University Hospital.

Toshiyuki Yano (T)

Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine.

Takanori Tsukada (T)

Cardiac Rehabilitation Center, Social Welfare Corporation, Hokkaido Social Work Association Obihiro Hospital.

Hidemichi Kouzu (H)

Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine.

Suguru Honma (S)

Department of Rehabilitation, Sapporo Cardiovascular Hospital.

Takuya Inoue (T)

Division of Rehabilitation, Sapporo Medical University Hospital.

Yuhei Takamura (Y)

Division of Rehabilitation, Sapporo Medical University Hospital.

Ryohei Nagaoka (R)

Division of Rehabilitation, Sapporo Medical University Hospital.

Tomoyuki Ishigo (T)

Division of Hospital Pharmacy, Sapporo Medical University Hospital.

Ayako Watanabe (A)

Division of Nursing, Sapporo Medical University Hospital.

Katsuhiko Ohori (K)

Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine.
Department of Cardiology, Hokkaido Cardiovascular Hospital.

Masayuki Koyama (M)

Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine.

Nobutaka Nagano (N)

Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine.

Takefumi Fujito (T)

Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine.

Ryo Nishikawa (R)

Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine.

Hiroyuki Takashima (H)

Division of Radiology and Nuclear Medicine, Sapporo Medical University Hospital.

Akiyoshi Hashimoto (A)

Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine.
Division of Health Care Administration and Management, Sapporo Medical University School of Medicine.

Masaki Katayose (M)

Department of Public Health, Sapporo Medical University School of Medicine.
Second Division of Physical Therapy, School of Health Sciences, Sapporo Medical University.

Tetsuji Miura (T)

Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH